Is your hip cartilage damage suitable for ChondroFiller injection?

The answer depends less on how much pain you have and more on the current state of your hip joint. ChondroFiller injection works by recruiting your own repair cells into a focal defect — which means the joint around it must still be capable of supporting that biological process.

The typical candidate has a contained, full-thickness cartilage lesion (ICRS Grade III or IV) on the acetabular surface or the femoral head, usually between 2 and 4 cm² in area. These lesions are frequently associated with femoroacetabular impingement (FAI), where abnormal joint geometry concentrates stress on a specific area of cartilage over time. The cartilage surrounding the defect must still be healthy: ChondroFiller integrates with adjacent tissue, and it cannot compensate for cartilage that has already been lost across the joint more broadly.

The single most important selection boundary is Tönnis grade — a staging system that measures the degree of osteoarthritic change visible on X-ray. Grade ≤1 indicates early, minimal degeneration. In the Mazek 2021 prospective cohort, the primary published dataset for ChondroFiller use in the hip, patients with Tönnis grade 2 or 3 at baseline had uniformly poor outcomes, with two of the evaluable patients ultimately proceeding to total hip replacement. The implication is unambiguous: once OA has progressed beyond Tönnis 1, the joint environment is unlikely to support the repair process the scaffold is designed to initiate.

ChondroFiller injection is a joint-preservation strategy for early, focal damage — not a rescue option once cartilage loss has become irreversible. Pre-procedure MRI is the required first clinical step, used to confirm defect size and geometry, assess the surrounding cartilage, and verify that the overall joint health meets the treatment threshold.

How ChondroFiller recruits your own cells to repair cartilage

Unlike corticosteroids or hyaluronic acid, which work on symptoms rather than structure, ChondroFiller is a biological scaffold — its job is to create the right environment for the joint to repair itself.

The material is a cell-free, acid-extracted Type I collagen hydrogel. It contains no donor cells of any kind. When injected under image guidance into the defect site, it self-sets into a solid gel within approximately 3–5 minutes, conforming to the contours of the lesion. What happens next is where the biology begins.

The collagen matrix acts as a physical template, drawing the patient's own progenitor cells in from two nearby sources: the synovium (the joint lining) and the subchondral bone beneath the defect. These cells migrate into the scaffold and gradually differentiate, producing the collagen and proteoglycans that form repair tissue. The process is known as acellular matrix-induced chondrogenesis — the scaffold initiates and supports repair without supplying cells itself.

Over 6–24 months the collagen gradually biodegrades, but the biological repair it has initiated continues beyond resorption. Laboratory confirmation of this mechanism comes from a 2025 ex vivo human osteochondral study, in which ChondroFiller-treated defects showed a 2.4-fold increase in DNA content by day 14 — direct evidence of meaningful cellular recruitment into the scaffold.

The result is a treatment that supports the body's own repair processes rather than simply masking pain: the scaffold provides the structure; the patient's biology does the building.

What the clinical evidence shows for the hip

The most concrete outcome figure from the published hip dataset is a mean improvement of approximately 30 points on the modified Harris Hip Score — a clinically meaningful gain across pain, function, and daily activity that held over a follow-up period of up to five years. This comes from the Mazek 2021 prospective cohort (n=26), in which patients with FAI and acetabular lesions greater than 2 cm² were followed for between one and five years; 17 of 21 evaluable patients at that point had achieved good or excellent results.

The total hip replacement figure within the same group is the more telling joint-preservation statistic: only 2 of the 21 patients went on to require joint replacement over that period. For patients seeking to delay or avoid major surgery, this is the number that matters most — and it comes with the caveat that every patient in the good-or-excellent category met strict baseline criteria.

The Tönnis 2–3 subgroup fared uniformly poorly, reinforcing rather than contradicting what was established earlier in this article: once the wider joint has deteriorated beyond Tönnis grade 1, the biological environment is unlikely to sustain the repair process the scaffold is designed to initiate.

Two limitations warrant straightforward acknowledgement. The cohort is small at 26 patients, and the evidence base for the current ultrasound-guided injectable delivery route — as distinct from the arthroscopic approach used in Mazek's study — does not yet include large randomised controlled trials or long-term comparative data against hip replacement timing. These gaps matter when weighing what the existing figures can reasonably be asked to support.

The ChondroFiller injection itself — what to expect

On the day of treatment, ChondroFiller injection is performed as an outpatient procedure under local anaesthetic — no general anaesthetic, no theatre booking, no overnight stay. The hip joint is accessed via a fine needle, with the collagen material delivered directly to the defect site under real-time imaging.

Image guidance is not optional. A 2016 systematic review by Hoeber et al., covering 120 citations, found that landmark-guided hip injections achieved accurate intra-articular placement in only 72% of cases (95% CI 56–85%), compared with 100% for image-guided techniques (p<0.0001). The anatomy of the anterior hip capsule is the reason: the lateral circumflex femoral artery crosses the capsule at a position that varies between patients and cannot be predicted from the skin surface alone. Ultrasound guidance allows the clinician to visualise the needle path in real time, confirming safe placement before any material is delivered. This is a precision requirement, not a precautionary add-on.

Once placement is confirmed, the collagen self-sets within the joint in a matter of minutes. The active procedure is brief.

The weeks that follow require some care. A 2024 biomechanical study using porcine osteochondral specimens found that ChondroFiller did not reduce loading damage to the opposing cartilage surface in the early phase — an effect the authors attributed to the initial mechanical instability of the hydrogel before stable defect filling is established. In practical terms, protected weight-bearing is required in the period immediately after injection; full loading should be avoided until the gel has had time to consolidate within the defect and the repair process has begun.

ChondroFiller injection versus other hip injections

Comparing options directly clarifies what each can and cannot achieve in the hip.

Corticosteroid injections have a legitimate short-term role in acute flare management, but a 2025 meta-analysis (PROSPERO CRD42024526221) found intra-articular corticosteroids provide no statistically significant improvement over placebo on WOMAC pain scores at two months (p=0.05), and no meaningful advantage over hyaluronic acid at six months (p=0.46) in hip OA. They play no part in cartilage restoration.

PRP outperforms hyaluronic acid on short-term functional scores — a 2025 study in 150 hip OA patients found greater improvements in VAS, WOMAC, and Harris Hip Score at 3, 6, and 12 months (p<0.05) — but the authors noted the changes were small and the two groups showed no clinically meaningful separation. Neither PRP nor HA addresses the underlying structural deficit.

ChondroFiller injection occupies a different category. Its mechanism — recruiting the patient's own progenitor cells into a collagen scaffold — depends on the biological environment being capable of sustaining that repair process. This is precisely why the Tönnis ≤1 threshold matters: in a joint already compromised by widespread degeneration, no injection can substitute for cartilage that is no longer present to support integration.

For more advanced cases, some specialist centres combine ChondroFiller with Arthrosamid, a polyacrylamide hydrogel used for synovial cushioning. The two products serve distinct roles: ChondroFiller provides the regenerative scaffold component, while Arthrosamid acts as a non-regenerative mechanical buffer within the joint. They are not interchangeable, and they should not be described as a single blended therapy. Evidence for combination protocols of this kind remains preliminary, drawn largely from specialist clinic experience rather than peer-reviewed trial data.

Getting assessed at the London Cartilage Clinic

An assessment at the London Cartilage Clinic begins with imaging review. Before any treatment is discussed, the treating clinician examines pre-existing MRI to confirm defect geometry, assess the integrity of surrounding cartilage, and establish where on the staging spectrum the joint currently sits. That staging conversation is the substance of the appointment: patients typically leave with a clear picture of whether the biological conditions for ChondroFiller injection are present, and if not, what the realistic alternatives are.

Professor Paul Y. F. Lee leads the delivery of Liquid Cartilage™ at the clinic; precision of image-guided placement is known to affect outcome for a scaffold this delivery-sensitive, and individual clinical experience with the technique matters.

The London Cartilage Clinic on Harley Street is the UK's certified delivery centre for ChondroFiller. Because the treatment depends on a joint environment that can still support active repair, the timing of that first conversation is itself clinically relevant. To arrange an assessment, visit londoncartilage.com.

1. [1] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
2. [2] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
3. [3] Pain management of hip OA with corticosteroids vs injection therapies: systematic review and meta-analysis. (2025). https://doi.org/10.1186/s12891-025-08666-0 https://doi.org/10.1186/s12891-025-08666-0
4. [4] Controlled, randomized multicenter study: ChondroFiller liquid vs microfracturing for focal cartilage defects of the knee. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
5. [5] Cartilage reconstruction using Chondrofiller in intra-articular distal radius fractures. (2025). https://doi.org/10.1186/s42836-025-00333-y https://doi.org/10.1186/s42836-025-00333-y
6. [6] Comparative efficacy of PRP vs ultrasound-guided HA injection in hip osteoarthritis. (2025). https://doi.org/10.1080/07853890.2025.2524091 https://doi.org/10.1080/07853890.2025.2524091